ERNA Eterna Therapeutics, Inc.: Forward Price-to-Revenue Multiple

Corporate emblem and logo of Eterna Therapeutics, Inc. (ERNA)

Eterna Therapeutics (ERNA) minimizes scientific risks by allocating resources across various cell engineering programs. A safe method for the temporary modification of genetic code creates a unique advantage in blood therapy. However, the lack of current commercial revenue and the preclinical testing stage are weighing on the share price. The forward P/S valuation metric reflects the relationship between value and projected sales, where the value 26.40 expresses the level of this metric.

Eterna Therapeutics, Inc. - ERNA Market Cap to Future Revenue Ratio (period 11/15/2023 - 11/09/2025)

Eterna Therapeutics Inc. - analytical breakdowns and key metrics (ERNA)

- current price and projected stock value:
Stock Price Eterna Therapeutics Inc.|ERNA - Average Forecast Price
- company stock capitalization data:
Market Valuation Eterna Therapeutics|ERNA - Aggregate Business Value
- business book valuation details:
Book Value per Share Eterna Therapeutics|ERNA - Total Stockholders' Equity|Market Value to Book Value Ratio eternatx.com|ERNA - Aggregate Asset Value
- debt obligations and liquidity statistics:
Debt to Equity Eterna Therapeutics|ERNA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Eterna Therapeutics, Inc.|ERNA - Company Aggregate Debts|Debt to Book Value Eterna Therapeutics, Inc.|ERNA - Company Long-Term Loans and Borrowings|Company Current Liabilities Eterna Therapeutics|Quick Ratio eternatx.com
- financial results and valuation multiples details:
ERNA - Final Profit|Projected Future Earnings Eterna Therapeutics|ERNA - Market Cap to Earnings|Future Price to Earnings Eterna Therapeutics|ERNA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Eterna Therapeutics|ERNA - Operating profit EBITDA|Earnings per share for the last twelve months Eterna Therapeutics|ERNA - Earnings per one share for the last 12 months|Quarterly EPS earnings growth eternatx.com|ERNA - Earnings per share growth rate in current year|Expected earnings per share growth for next year Eterna Therapeutics
- revenue and sales details:
ERNA - Revenue and Sales Volume|Company Future Sales Volume Eterna Therapeutics Inc.|ERNA - Market Cap to Sales Volume|Forward P/S Multiple Eterna Therapeutics Inc
Fundamental company analysis:Eterna Therapeutics Inc. (ERNA)
Original product of eternatx.com

Forward P/S measures the market value of a business relative to projected revenue, allowing investors to assess the extent of sales growth expectations priced in. Analyzing the P/S expectations for Eterna Therapeutics (ERNA) reveals how production outsourcing via CMO platforms reduces capital expenditures, making the asset's current valuation more resilient to operational risks.

Key competitors

TG Therapeutics - Forward Price-to-Revenue Multiple|Forward P/S Multiple Arcellx Therapeutics ACLX|discmedicine.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio syndax.com|Kura Oncology (KURA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ADC Therapeutics Corp|FHTX (foghorntx.com) - Forward P/S Multiple|Price-to-Projected Revenue Ratio VOR|Forward Price-to-Revenue Multiple NKTX (Nkarta, Inc.)|Price to Expected Revenue Ratio COEP|Forward P/S Multiple ATNM (Actinium Pharma)|Estrella Immunopharma Inc - Price-to-Projected Revenue Ratio|CASI Pharmaceuticals, Inc. - Forward P/S Multiple|Forward Price to Sales MRKR (Marker Therapeutics Inc)|IN8bio, Inc. - Market Cap to Expected Sales Ratio|GT Biopharma, Inc. - Forward Price to Sales|APTO (Aptose Biosciences) - Forward P/S Multiple|BPTH: Forward Price to Sales|Forward P/S Multiple MEIP|VINC (Vincerx Pharma) - Forward Price to Sales